Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News

Latest news

ELCC: QoL in ENSURE study of first-Line Erlotinib vs. Gemcitabine/Cisplatin in Asian patients with EGFR mutation-positive NSCLC

31 Mar 2014
ELCC: QoL in ENSURE study of first-Line Erlotinib vs. Gemcitabine/Cisplatin in Asian patients with EGFR mutation-positive NSCLC

Improved quality of life with erlotinib in a randomised phase III study

ENSURE, a randomised, phase III study, met its primary endpoint of improved progression-free survival (PFS) with erlotinib vs. gemcitabine/cisplatin in Asian patients with epidermal-growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).

To read the rest of this story visit the ESMO site.

Related News

Centre initiates groundbreaking clinical trial with oncolytic virus for non-small cell lung cancer 1 May 2024
Hospital first-in-paediatrics to use technology that lights up lung cancer during surgery 1 May 2024
Positive CHMP opinion establishes amivantamab as a new treatment option in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC 30 Apr 2024
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer 23 Apr 2024
AACR 2024: Researchers show oestrogen metabolites contribute to development of lung cancer among people who never smoked 9 Apr 2024
‘Junk DNA’ no more: Investigators develop method of identifying cancers from repeat elements of genetic code 14 Mar 2024
Setting realistic expectations for recovery after robotic lung surgery 13 Mar 2024
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications 7 Mar 2024
Study unravels the earliest cellular genesis of lung adenocarcinoma 29 Feb 2024
Genetic signature may predict response to immunotherapy for non-small cell lung cancer 26 Feb 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation